Next-Generation Sequencing Market By Product Type (Sequencers, Consumables, Analyzers), By Application (Diagnostics {Cancer Diagnostics, Infectious Disease Diagnostics, Others} Research & Development {Genomic research, Transcriptomics, Epigenomics} Agriculture and Animal Research {Crop genomics, Livestock genomics} Environmental & Forensic), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Others), By End-User (Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical and Biotechnology Companies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Next-Generation Sequencing market accounted for USD 18.0 Billion in 2024 and is expected to reach USD 164.8 Billion by 2035, growing at a CAGR of around 22.3% between 2025 and 2035. The Next-Generation Sequencing, or NGS, market refers to that part of the industry focused on advanced sequencing technologies that allow for very fast and high-throughput analysis of DNA and RNA. Thus, NGS is highly applied in the healthcare sectors, with ranges including genetic diagnosis, cancer genomics, and personal medicine, much more accurate and rapid ways for identification and treatment plans for diseases. This tool also has other applications in research, where it can be used to investigate gene expression, genetic variability, and mutations. It can also be applied in agriculture, mainly in crop yield enhancement and livestock breeding. Market driving factors include the reduction of sequencing cost, more advancement in the technologies applied for sequencing, and more application of AI and machine learning approaches for data analysis. With the rise in the demand for precision medicine, NGS is conquering new territories and applications by penetrating further into clinical diagnostics, drug development, and environment-related studies.

Report Scope:

Market Dynamics

• Growing Role of Next-Generation Sequencing in Genetic Disease Diagnosis and Treatment

Many factors contribute to the steadily growing interest in Next-Generation Sequencing in terms of genetic disease diagnosis and therapy. The cost has indeed come down and so has the time required for sequencing, making it accessible for applications in clinics. NGS further allows for full genetic analysis and aids in the detection of rare genetic mutations, thus providing a personalized direction for treatment. This trend is further fueled by the growing number of genetic disorders and increased awareness along with early detection capabilities.

Further, the evolving prowess of precision medicine by tailoring treatment according to individual genetic profiles fuels this trend. As reported by the U.S. NHGRI estimates over 1 in 2,000 children is born with a genetic disorder. Genomic testing through Next-Generation Sequencing has provided a critical tool for conditions such as cystic fibrosis, Duchenne muscular dystrophy, and several cancers. This trend is supported by coordination between healthcare providers, research institutions, and biotechnology companies that foster enhanced genetic diagnostics and therapeutics.

• Revolutionizing Cancer Diagnosis and Treatment with Next-Generation Sequencing

Next-generation sequencing was used for the first time in the diagnosis and treatment of cancer, revolutionizing the methods. Patients are receiving better care with more accurate treatments and a person-specific approach to therapy because it makes possible the identification of which genetic mutation caused cancer. Clinicians will thus be able to target their therapies and predict patient responses more effectively. This means that the treatment will then prove to be more effective with fewer side effects. The more cancer comes to be appreciated as a genetically based disease, the higher the demand for NGS in oncology has proven to be. The technology also enables minimal residual disease monitoring, which is the detection of possible relapses.

According to the National Cancer Institute, cancer causes nearly 1 in every 4 deaths in the U.S. This reflects a significant need to develop advanced diagnostic and therapeutic methods, and Next-Generation Sequencing takes the lead in this aspect with improvement in early diagnosis, treatment stratification, and long-term monitoring of patients with cancer. This has been increasingly followed by adoption in the oncology setting, driven by further clinical advances and significant funding in genomic research.

• Shortage of Skilled Bioinformaticians and Genomic Scientists Hindering Next-Generation Sequencing Adoption

A severe limitation of the wide application of Next-Generation Sequencing is that few individuals have been trained in bioinformatics and genomic science. Indeed, NGS generates huge amounts of complex information. Without experts in the processing, interpretation, and analysis of such data, the work will not be correctly done. There are increasing demands for these professionals who cannot always be serviced, particularly in smaller or less-resourced regions, which makes it challenging for most institutions to apply the technologies very effectively.

According to a report by the U.S. Department of Energy's Office of Science, bioinformatics had become one of the fastest-growing fields in science, while skilled professionals were sorely underrepresented in the existing workforce. This skill gap will impede the quick integration of Next-Generation Sequencing in clinical and research studies, thus potentially curtailing its ability to drive innovation in personalized medicine and disease management.

• Expanding Opportunities for NGS in Agriculture Enhancing Crop Genetics and Food Security

The prospects for farming through Next-Generation Sequencing are bright, especially because this technology is empowering crop genetics food security, and sustainability. High-resolution capabilities in the genetic scrutiny of crops are provided for by NGS, hence finding the desirable traits, such as resistance to pests, drought tolerance, and enhanced nutrient content. Genomic selection accelerates the breeding process of crops that are yield-intensive and resilient enough to face changing climate conditions.

According to the USDA, genomic tools, such as Next-Generation Sequencing, are essential to advancements in agricultural productivity, whereas NGS-based innovations have begun to improve crops like corn, wheat, and soybeans, NGS can also be used to potentially reduce reliance on chemical pesticides by controlling pests that result in losses to agriculture, supporting sustainable farming practices. These technologies are essential to ensure sustainable food security as food demand is rising commensurate with a rise in the population of the world.

• Advancing Pathogen Monitoring and Infectious Disease Detection

Next-generation sequencing provides a boundless scope for the extension of pathogen monitoring and detection of infectious diseases. Next-generation sequencing allows for high-throughput sequencing of microbial genomes and thereby accelerates pathogen identification, which involves bacteria and viruses along with fungi in complex clinical samples. It further accelerates diagnosis, helps in antibiotic resistance detection, and gives detailed insights into the genetic makeup of pathogens for the tracking of outbreaks and the elucidation of their evolution.

The U.S. Centers for Disease Control and Prevention highlights Next-Generation Sequencing as the most significant tool in improving infectious disease surveillance since the NGS has been applied to the identification of emerging pathogens, and monitoring the viral mutations; for example, during the COVID-19 pandemic, NGS enables the diagnosis of a rare or hardly cultured pathogens. With such capabilities, NGS has been assisting in the re-modeling of diagnosis, surveillance, and control of infectious diseases along with new possibilities in public health management.

Industry Experts Opinion

"Through research conducted globally, there is a significant body of evidence demonstrating the clinical utility of comprehensive genomic profiling for patients with advanced cancer,"

• Vivek Subbiah, MD, chief, Early-Phase Drug Development at Sarah Cannon Research Institute

Segment Analysis

Based on the product type, the Next-Generation Sequencing market is categorized into sequencers, consumables, and analyzers. Sequencers include high-throughput instruments like benchtops and handheld models. Consumables cover reagents and kits, while analyzers involve devices and software for data interpretation and processing. Among these, consumables are the leading segment due to their recurring demand in NGS workflows.

Based on the applications, the Next-Generation Sequencing market is vast and widespread across diagnostics and research. Diagnostics include cancer and infectious diseases diagnostics, besides other clinical applications. NGS plays a very important role in genomic research, transcriptomics, epigenomics, and agriculture in research and development. It represents a very high utility in both healthcare and scientific advancements, as usage is ever-increasing in crop and livestock genomics besides environmental and forensic studies. The primary application is cancer diagnostics, mostly boosted by the growing need for personal medicine and targeted therapies within oncology.

The market technologies of NGS include Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, and Nanopore Sequencing, all of which have special advantages. The most widely applied is Sequencing by Synthesis, mainly due to its accuracy and scalability for the high-throughput application. The growing attention of the technologies is for their real-time data generation and portability, which allows them to have considerable potential in onsite applications. Sequencing by Synthesis is the leading technology for full genomic analysis because it has been more widely implemented in the clinical and research fields.  

Regional Analysis

North America next-generation sequencing market is dominated by advanced healthcare infrastructure, high research funding, and strong adoption of precision medicine. In the United States, it is leading in innovations for NGS, with both private companies and government agencies such as the NIH providing major investments in genomics research and development. The region is contributing through a developing number of NGS-based diagnostic applications, especially in the fields of oncology and infectious diseases. Growth in genetic disorders is an added factor due to the increasing demand for personalized medicine. Additionally, North American countries are known to have favorable regulatory environments and healthcare reimbursement policies that enable support for the use of NGS technologies in clinical practices.

The Asia Pacific Next-Generation Sequencing market is anticipated to witness steady growth, driven by advancements in biotechnology and growing healthcare needs coupled with high government support for genomics research. NGS technologies are widely adopted in the Asia Pacific for clinical diagnosis, precision medicine, and genomics research. It is utilized widely in the diagnostics of cancer as well as personalized treatments, agriculture, and environmental genomics. The growing incidence of genetic diseases and the quest for more available and efficient diagnostic tools fuels further demand for NGS solutions. Further-scale genomic studies and research collaborations in various Asian countries are said to improve healthcare delivery and advance drug development. Continued innovation and investment in healthcare infrastructure will fuel growth in the Asia Pacific NGS market for the coming years.

Competitive Landscape

The Next-Generation Sequencing market is highly competitive having major participants such as W2O Group, Edelman, Havas Health & You, and Public Health stand out prominently. They offer a wide range of services such as marketing strategies, public relations, and digital communication that are meant for the health sector. Recent developments have pushed healthcare marketers to become more data-driven and digitally transformed. For instance, Klick Health has enhanced its digital capabilities and therefore increased patient engagement, while Fishawack Health has recently acquired the London-based agency Revelo to improve on global coordination efforts. As a result, Deloitte Digital has prioritized the use of AI in its healthcare marketing strategies. All these factors signify that changes keep occurring in this market segment necessitating the adoption of distinctive strategies if competition is to be maintained.

Next-Generation Sequencing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In August 2024, TruSight Oncology Comprehensive became the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. This 500+ gene biomarker test enhances access to localized precision oncology, offering more personalized treatment options for cancer patients.
• In May 2024, CorePath Laboratories partnered with Genomic Testing Cooperative (GTC) to enhance NGS diagnostics for hematologic neoplasms and solid tumors. This collaboration integrates targeted DNA and RNA profiling with pathology tests like IHC, flow cytometry, and FISH, providing clinicians with more accurate and timely diagnostic information.

Report Coverage:

By Product Type

• Sequencers
• Consumables
• Analyzers

By Application

• Diagnostics
  • Cancer Diagnostics
  • Infectious Disease Diagnostics
  • Others
• Research & Development
  • Genomic research
  • Transcriptomics
  • Epigenomics
• Agriculture and Animal Research
  • Crop genomics
  • Livestock genomics
• Environmental & Forensic

By Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single-Molecule Real-Time Sequencing
• Nanopore Sequencing
• Others

End-User

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical and Biotechnology Companies

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• 10x Genomics
• Oxford Nanopore Technologies
• BGI Group
• Roche Diagnostics
• Agilent Technologies, Inc.
• PerkinElmer, Inc.
• Macrogen, Inc.
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Veracyte
• Ion Torrent
• New England Biolabs
• Vela Diagnostics

Frequently Asked Questions (FAQs)